Paper25535693
Molecularly targeted therapies in non-small-cell lung cancer annual update 2014.
Morgensztern D and 23 others. J Thorac Oncol, 2015. Cited by 112 papers, by iCite.
Cite this record
ConductScience Library. Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. Papers, record 25535693. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/25535693
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinoma, Non-Small-Cell Lung | Major topic |
| Lung Neoplasms | Major topic |
| Genetic Therapy | |
| Humans | |
| Immunotherapy | |
| Molecular Targeted Therapy | |
| Randomized Controlled Trials as Topic |
Source PubMed
Grants8
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| P30 CA006973 | NCI NIH HHS | United States | P30CA006973 | PubMed and NIH | NIH RePORTER |
| T32 CA009071 | NCI NIH HHS | United States | T32CA009071 | PubMed and NIH | NIH RePORTER |
| K12 CA167540 | NCI NIH HHS | United States | K12CA167540 | PubMed and NIH | NIH RePORTER |
| R21 CA170063 | NCI NIH HHS | United States | R21CA170063 | PubMed and NIH | NIH RePORTER |
| R01 CA182746 | NCI NIH HHS | United States | R01CA182746 | PubMed and NIH | NIH RePORTER |
| UL1 TR000142 | NCATS NIH HHS | United States | UL1TR000142 | PubMed and NIH | NIH RePORTER |
| K23 CA149079 | NCI NIH HHS | United States | K23CA149079 | PubMed and NIH | NIH RePORTER |
| K12CA157688 | NIH | NIH RePORTER |
References283
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 23856031 | Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models. | Cancer Lett | 2013 | https://conductscience.org/library/papers/23856031 | PubMed |
| 2 | 19692680 | Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. | N Engl J Med | 2009 | https://conductscience.org/library/papers/19692680 | PubMed |
| 3 | 21941284 | A decade of exploring the cancer epigenome - biological and translational implications. | Nat Rev Cancer | 2011 | https://conductscience.org/library/papers/21941284 | PubMed |
| 4 | 1679529 | Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines. | Oncogene | 1991 | https://conductscience.org/library/papers/1679529 | PubMed |
| 5 | 23922022 | Volumetric tumor growth in advanced non-small cell lung cancer patients with EGFR mutations during EGFR-tyrosine kinase inhibitor therapy: developing criteria to continue therapy beyond RECIST progression. | Cancer | 2013 | https://conductscience.org/library/papers/23922022 | PubMed |
| 6 | 23806793 | Fibroblast growth factor receptor 1 (FGFR1) copy number is an independent prognostic factor in non-small cell lung cancer. | Lung Cancer | 2013 | https://conductscience.org/library/papers/23806793 | PubMed |
| 7 | 23770567 | Mutational heterogeneity in cancer and the search for new cancer-associated genes. | Nature | 2013 | https://conductscience.org/library/papers/23770567 | PubMed |
| 8 | 24302556 | Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer. | Cancer Discov | 2014 | https://conductscience.org/library/papers/24302556 | PubMed |
| 9 | 22761469 | Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. | Clin Cancer Res | 2012 | https://conductscience.org/library/papers/22761469 | PubMed |
| 10 | 23546521 | The future of epigenetic therapy in solid tumours--lessons from the past. | Nat Rev Clin Oncol | 2013 | https://conductscience.org/library/papers/23546521 | PubMed |
| 11 | 17047648 | A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. | Br J Cancer | 2006 | https://conductscience.org/library/papers/17047648 | PubMed |
| 12 | 22837387 | Transforming fusions of FGFR and TACC genes in human glioblastoma. | Science | 2012 | https://conductscience.org/library/papers/22837387 | PubMed |
| 13 | 22776234 | The genetics and biology of KRAS in lung cancer. | Chin J Cancer | 2013 | https://conductscience.org/library/papers/22776234 | PubMed |
| 14 | 21711248 | Fibroblast growth factors and their receptors in cancer. | Biochem J | 2011 | https://conductscience.org/library/papers/21711248 | PubMed |
| 15 | 15735036 | Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. | Cancer Res | 2005 | https://conductscience.org/library/papers/15735036 | PubMed |
| 16 | 22975805 | The transcriptional landscape and mutational profile of lung adenocarcinoma. | Genome Res | 2012 | https://conductscience.org/library/papers/22975805 | PubMed |
| 17 | 22327623 | RET, ROS1 and ALK fusions in lung cancer. | Nat Med | 2012 | https://conductscience.org/library/papers/22327623 | PubMed |
| 18 | 23887156 | ROS1 immunohistochemistry for detection of ROS1-rearranged lung adenocarcinomas. | Am J Surg Pathol | 2013 | https://conductscience.org/library/papers/23887156 | PubMed |
| 19 | 20826737 | Improved endpoints for cancer immunotherapy trials. | J Natl Cancer Inst | 2010 | https://conductscience.org/library/papers/20826737 | PubMed |
| 20 | 23533264 | Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. | Cancer Discov | 2013 | https://conductscience.org/library/papers/23533264 | PubMed |
Cited by68
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 112 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41021160 | Mechanistic evaluation of hyperoside against non-small cell lung cancer: a combined approach of network pharmacology and in vitro experimental validation. | Discov Oncol | 2025 | https://conductscience.org/library/papers/41021160 | PubMed |
| 40965349 | EGFR Mutation Detection in Whole Slide Images of Non-Small Cell Lung Cancers Using a Two-Stage Deep Transfer Learning Approach. | Cancer Med | 2025 | https://conductscience.org/library/papers/40965349 | PubMed |
| 40916818 | Radiogenomics-based prediction of KRAS and EGFR gene mutation in non-small cell lung cancer patients. | Zhong Nan Da Xue Xue Bao Yi Xue Ban | 2025 | https://conductscience.org/library/papers/40916818 | PubMed |
| 40805126 | Orthotopically Implanted Murine Lung Adenocarcinoma Cell Lines for Preclinical Investigations. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/40805126 | PubMed |
| 40568577 | Multi-omics analysis untangles the crosstalk between intratumor microbiome, lactic acid metabolism and immune status in lung squamous cell carcinoma. | Front Immunol | 2025 | https://conductscience.org/library/papers/40568577 | PubMed |
| 40292291 | Plasma IgG and IgM autoantibodies to COPT1 as potential biomarkers for detection of non-small cell lung cancer. | Front Immunol | 2025 | https://conductscience.org/library/papers/40292291 | PubMed |
| 39754146 | Aidi injection inhibits the migration and invasion of gefitinib-resistant lung adenocarcinoma cells by regulating the PLAT/FAK/AKT pathway. | Chin Med | 2025 | https://conductscience.org/library/papers/39754146 | PubMed |
| 39679460 | Emerging AXL Inhibitors in Oncology: Chemical and Biological Advances in Targeted Cancer Therapy. | Anticancer Agents Med Chem | 2025 | https://conductscience.org/library/papers/39679460 | PubMed |
| 38989152 | Assessing the benefits and safety profile of incorporating poly ADP-ribose polymerase (PARP) inhibitors in the treatment of advanced lung cancer: a thorough systematic review and meta-analysis. | Front Pharmacol | 2024 | https://conductscience.org/library/papers/38989152 | PubMed |
| 38707278 | Dacomitinib exhibits promising activity against the rare HER2 exon 20 insertion M774delinsWLV in lung cancer: A case report and literature review. | Heliyon | 2024 | https://conductscience.org/library/papers/38707278 | PubMed |
| 38398169 | Drug Response of Patient-Derived Lung Cancer Cells Predicts Clinical Outcomes of Targeted Therapy. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/38398169 | PubMed |
| 36031613 | Pyrotinib combined with apatinib for targeting metastatic non-small cell lung cancer with HER2 alterations: a prospective, open-label, single-arm phase 2 study (PATHER2). | BMC Med | 2022 | https://conductscience.org/library/papers/36031613 | PubMed |
| 35946957 | βIII-tubulin suppression enhances the activity of Amuvatinib to inhibit cell proliferation in c-Met positive non-small cell lung cancer cells. | Cancer Med | 2023 | https://conductscience.org/library/papers/35946957 | PubMed |
| 35799269 | Identification of a cytokine-dominated immunosuppressive class in squamous cell lung carcinoma with implications for immunotherapy resistance. | Genome Med | 2022 | https://conductscience.org/library/papers/35799269 | PubMed |
| 35284122 | Mutational characteristics of young and elderly gastric cancer: a comparative study. | J Gastrointest Oncol | 2022 | https://conductscience.org/library/papers/35284122 | PubMed |
| 35117179 | Functional analysis of long-chain non-coding RNA in oral squamous cell carcinoma. | Transl Cancer Res | 2020 | https://conductscience.org/library/papers/35117179 | PubMed |
| 34820522 | A proposal for score assignment to characterize biological processes from mass spectral analysis of serum. | Clin Mass Spectrom | 2020 | https://conductscience.org/library/papers/34820522 | PubMed |
| 34711122 | MiR-133b suppresses the proliferation, migration and invasion of lung adenocarcinoma cells by targeting SKA3. | Cancer Biol Ther | 2021 | https://conductscience.org/library/papers/34711122 | PubMed |
| 34599863 | Driver gene alterations profiling of Chinese non-small cell lung cancer and the effects of co-occurring alterations on immunotherapy. | Cancer Med | 2021 | https://conductscience.org/library/papers/34599863 | PubMed |
| 34572523 | Shifting Gears in Precision Oncology-Challenges and Opportunities of Integrative Data Analysis. | Biomolecules | 2021 | https://conductscience.org/library/papers/34572523 | PubMed |
Genes142
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/25535693
GET https://conductscience.org/api/papers/v1/25535693/authors?page=2